On Jun. 23, 2022, Innovation Pharmaceuticals reported that Brilacidin, the Company’s defensin-mimetic drug candidate exhibiting broad-spectrum antiviral activity,…
On Mar. 7, 2022, Innovation Pharma announced the Company was conducting full data analysis of the Phase 2…
On Nov. 12, 2021, Innovation Pharma announced the Company was conducting full data analysis of the Phase 2…
On Nov. 11, 2021, Innovation Pharma reported topline results from the Companyﾒs Phase 2 clinical trial of Brilacidin…
On Nov. 3, 2021, Innovation Pharma announced that the Company had received confirmation that hard lock of the…
On Aug. 12, 2021, Innovation Pharma released information regarding the status of its randomized, double-blind, placebo-controlled Phase 2…
On Jun. 3, 2021, Innovation Pharma announced that it had achieved full patient enrollment in its randomized, double-blind,…
On May 27, 2021, Innovation Pharmaceuticals announced that patient enrollment in the Companyﾒs 120-patient, Phase 2 clinical trial…
On May 27, 2021, Innovation Pharma announced that patient enrollment in the Company’s 120-patient, Phase 2 clinical trial…
On Apr. 28, 2021, Innovation Pharma announced that enrollment had surpassed 50 percent of the total targeted number…
On Apr. 5, 2021, Innovation Pharmaceuticals announced that an independent Data Monitoring Committee (DMC) completed its scheduled review…
On Mar. 10, 2021, Innovation Pharmaceuticals announced that a Machine Learning (Artificial Intelligence) model used to screen 1,482…
On Mar. 5, 2021, Innovation Pharmaceuticals reported that eight sites were participating in the Company’s international Phase 2…
On Mar. 2, 2021, Innovation Pharmaceuticals reported that eight sites were participating in the Companyﾒs international Phase 2…
On Feb. 26, 2021, Innovation Pharmaceuticals announced that after an interim review, by an independent Data Monitoring Committee…
On Jan. 29, 2021, Innovation Pharmaceuticals announced that the companyﾒs Phase 2 clinical trial of Brilacidin for treating…
On Jan. 14, 2021, Innovation Pharmaceuticals announced that the FDA had designated as a Fast Track development program…
On Dec. 21, 2020, Innovation Pharmaceuticals announced that the FDA had approved the Companyﾒs Investigational New Drug (IND)…
On Dec. 21, 2020, Innovation Pharma announced that the FDA had approved the Companyﾒs Investigational New Drug (IND)…
On Nov. 30, 2020, Innovation Pharmaceuticals announced additional independent preliminary laboratory research suggests Brilacidin, the Company’s flagship defensin…
On Nov. 16, 2020, Innovation Pharmaceuticals announced that an overseas Clinical Trial Application (CTA) has been submitted to…
On Nov. 2, 2020, Innovation Pharma announced receipt of written feedback from the FDA that is in general…
On Nov. 1, 2020, scientists announced that increasing evidence shows that both natural and synthetic antimicrobial peptides (AMPs),…
On Oct. 30, 2020, Innovation Pharma and George Mason University jointly announced completion of extensive laboratory testing supporting…
On Sept. 15, 2020, Innovation Pharma reported additional data from a U.S. Regional Biocontainment Laboratory (RBL) collected during…
On Aug. 24, 2020, Innovation Pharma reported receiving additional data from a U.S. Regional Biocontainment Laboratory (RBL) based…
On Aug. 4, 2020, Innovation Pharma reported receiving an update from a U.S. Regional Biocontainment Laboratory (RBL) based…
On Jul. 20, 2020, Innovation Pharma reported receiving new data from ongoing lab testing being conducted at a…
On Jul. 13, 2020, Innovation Pharma announced that, in parallel to previously reported manufacturing efforts, the Company had…
On Jul. 7, 2020, Innovation Pharma reported the latest developments related to research into Brilacidin as a potential…